首页 > 最新文献

Endocrinologia, Diabetes y Nutricion最新文献

英文 中文
Micro solutions for macro problems: Challenging thyroid and parathyroid function tests 宏观问题的微观解决方案具有挑战性的甲状腺和甲状旁腺功能测试
4区 医学 Q3 Nursing Pub Date : 2024-08-21 DOI: 10.1016/j.endinu.2024.06.003
Utku Soyaltin , Ayla Yildiz , Nurhilal Yusufoğlu , Emre İspir
{"title":"Micro solutions for macro problems: Challenging thyroid and parathyroid function tests","authors":"Utku Soyaltin , Ayla Yildiz , Nurhilal Yusufoğlu , Emre İspir","doi":"10.1016/j.endinu.2024.06.003","DOIUrl":"10.1016/j.endinu.2024.06.003","url":null,"abstract":"","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"71 10","pages":"Pages 456-458"},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142721778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential of insulin deprescription adding a GLP-1 receptor agonist as a therapeutic strategy to improve the metabolic profiles of patients with type 2 diabetes mellitus 添加 GLP-1 受体激动剂的胰岛素去势疗法是改善 2 型糖尿病患者代谢状况的一种潜在治疗策略
4区 医学 Q3 Nursing Pub Date : 2024-08-10 DOI: 10.1016/j.endinu.2024.05.013
Victor Perez de Arenaza Pozo, Jersy Cárdenas Salas, Clotilde Vázquez Martínez
{"title":"Potential of insulin deprescription adding a GLP-1 receptor agonist as a therapeutic strategy to improve the metabolic profiles of patients with type 2 diabetes mellitus","authors":"Victor Perez de Arenaza Pozo, Jersy Cárdenas Salas, Clotilde Vázquez Martínez","doi":"10.1016/j.endinu.2024.05.013","DOIUrl":"10.1016/j.endinu.2024.05.013","url":null,"abstract":"","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"71 9","pages":"Pages 405-407"},"PeriodicalIF":0.0,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142535308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hipotiroidismo posthemitiroidectomía. Prevalencia y marcadores predictivos. Comparación entre pacientes con bocio nodular eutiroideo e hipertiroideo 甲状腺切除术后甲状腺功能减退症。发病率和预测指标。甲状腺功能亢进和甲状腺功能亢进结节性甲状腺肿患者的比较。
4区 医学 Q3 Nursing Pub Date : 2024-08-01 DOI: 10.1016/j.endinu.2024.05.004

Background and objective

Posthemithyroidectomy hypothyroidism (PHH) is a relatively common complication (22-30%) for which we have no published information from our country. The objective of the study is to determine the prevalence of PHH and evaluate its predictive markers by comparing patients who had euthyroidism with those who had hyperthyroidism before hemithyroidectomy.

Patients and method

Retrospective observational cross-sectional study on 106 patients, 88 euthyroid before hemithyroidectomy and 18 hyperthyroid.

Results

Prevalence of PHH in euthyroid patients 42% (89.2% subclinical hypothyroidism; 10.8% manifest hypothyroidism) and in hyperthyroid patients 50% (77.8% subclinical hypothyroidism; 22.2% manifest hypothyroidism). Predictive markers in euthyroid patients: preoperative thyrotropin ≥ 2.2 mIU/L (OR: 4.278, 95% CI: 1.689-10.833; sensitivity: 54.1%, 95% CI: 38-70.1%; specificity:78.4%, 95% CI:67.1-89.7%), age ≥ 50 years (OR: 3.509, 95% CI: 1.438-8.563; sensitivity: 64.9%, 95% CI: 49.5-80.3%; specificity: 64.7%, 95% CI: 51.6-77.8%) and percentage of remainder lobe ≤ 19.6% (OR: 1.024, 95% CI: 1.002-1.046; sensitivity: 70.2%, 95% CI: 55.5-84.9%; specificity: 48.6%, 95% CI: 34.9-62.3%). Predictive marker in hyperthyroid patients: weight > 70 kg (OR: 28, 95% CI: 2.067-379.247; sensitivity: 88.9%, 95% CI: 68.4-100%; specificity: 88.9%, 95% CI:68.4-100%).

Conclusions

This is the first study in our country that demonstrates a prevalence of PHH above the average in euthyroid patients, which is slightly higher and more intense in hyperthyroid patients, and that recognizes the classic predictive markers in euthyroid patients but highlights a novel predictive marker marker in hyperthyroid patients, useful to assess a different risk of PHH when indicating hemithyroidectomy and to establish closer control of postoperative hormonal evolution.

背景和目的甲状腺半切术后甲状腺功能减退症(PHH)是一种相对常见的并发症(22%-30%),我国尚无这方面的公开信息。本研究的目的是通过比较甲状腺半切除术前甲状腺功能亢进症患者和甲状腺功能减退症患者,确定 PHH 的患病率并评估其预测指标。结果PHH在甲状腺功能亢进患者中的患病率为42%(89.2%为亚临床甲状腺功能减退症;10.8%为明显甲状腺功能减退症),在甲状腺功能亢进患者中的患病率为50%(77.8%为亚临床甲状腺功能减退症;22.2%为明显甲状腺功能减退症)。甲状腺功能亢进患者的预测指标:术前甲状腺素≥2.2 mIU/L(OR:4.278,95% CI:1.689-10.833;敏感性:54.1%,95% CI:38-70.1%;特异性:78.4%,95% CI:67.1-89.7%),年龄≥50 岁(OR:3.509,95% CI:1.438-8.563;敏感性:64.9%,95% CI:49.5-80.3%;特异性:64.7%,95% CI:51.6-77.8%)和余叶百分比≤19.6%(OR:1.024,95% CI:1.002-1.046;敏感性:70.2%,95% CI:55.5-84.9%;特异性:48.6%,95% CI:34.9-62.3%)。甲亢患者的预测指标:体重 70 千克(OR:28,95% CI:2.067-379.247;敏感性:88.9%,95% CI:68.4-100%;特异性:88.9%,95% CI:68.4-100%)。结论 这是我国的第一项研究,该研究显示甲状腺功能亢进患者的PHH发病率高于平均水平,而甲状腺功能亢进患者的PHH发病率略高且更高,该研究认可了甲状腺功能亢进患者的经典预测指标,但强调了甲状腺功能亢进患者的新型预测指标。
{"title":"Hipotiroidismo posthemitiroidectomía. Prevalencia y marcadores predictivos. Comparación entre pacientes con bocio nodular eutiroideo e hipertiroideo","authors":"","doi":"10.1016/j.endinu.2024.05.004","DOIUrl":"10.1016/j.endinu.2024.05.004","url":null,"abstract":"<div><h3>Background and objective</h3><p>Posthemithyroidectomy hypothyroidism (PHH) is a relatively common complication (22-30%) for which we have no published information from our country. The objective of the study is to determine the prevalence of PHH and evaluate its predictive markers by comparing patients who had euthyroidism with those who had hyperthyroidism before hemithyroidectomy.</p></div><div><h3>Patients and method</h3><p>Retrospective observational cross-sectional study on 106 patients, 88 euthyroid before hemithyroidectomy and 18 hyperthyroid.</p></div><div><h3>Results</h3><p>Prevalence of PHH in euthyroid patients 42% (89.2% subclinical hypothyroidism; 10.8% manifest hypothyroidism) and in hyperthyroid patients 50% (77.8% subclinical hypothyroidism; 22.2% manifest hypothyroidism). Predictive markers in euthyroid patients: preoperative thyrotropin ≥ 2.2 mIU/L (OR: 4.278, 95% CI: 1.689-10.833; sensitivity: 54.1%, 95% CI: 38-70.1%; specificity:78.4%, 95% CI:67.1-89.7%), age ≥ 50 years (OR: 3.509, 95% CI: 1.438-8.563; sensitivity: 64.9%, 95% CI: 49.5-80.3%; specificity: 64.7%, 95% CI: 51.6-77.8%) and percentage of remainder lobe ≤ 19.6% (OR: 1.024, 95% CI: 1.002-1.046; sensitivity: 70.2%, 95% CI: 55.5-84.9%; specificity: 48.6%, 95% CI: 34.9-62.3%). Predictive marker in hyperthyroid patients: weight<!--> <!-->&gt; 70<!--> <!-->kg (OR: 28, 95% CI: 2.067-379.247; sensitivity: 88.9%, 95% CI: 68.4-100%; specificity: 88.9%, 95% CI:68.4-100%).</p></div><div><h3>Conclusions</h3><p>This is the first study in our country that demonstrates a prevalence of PHH above the average in euthyroid patients, which is slightly higher and more intense in hyperthyroid patients, and that recognizes the classic predictive markers in euthyroid patients but highlights a novel predictive marker marker in hyperthyroid patients, useful to assess a different risk of PHH when indicating hemithyroidectomy and to establish closer control of postoperative hormonal evolution.</p></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"71 7","pages":"Pages 298-307"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141411385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influencia de la presencia y tipo de enfermedad cardiovascular sobre el riesgo de mortalidad de los pacientes con diabetes tipo 2: estudio DIABET-IC 心血管疾病的存在和类型对 2 型糖尿病患者死亡风险的影响:DIABET-IC 研究。
4区 医学 Q3 Nursing Pub Date : 2024-08-01 DOI: 10.1016/j.endinu.2024.03.008
José Antonio Gimeno Orna , Ana Belén Mañas Martínez , Luis Rodríguez Padial , Manuel Anguita Sánchez , Vivencio Barrios , Javier Muñiz García , Antonio Pérez Pérez , en representación de los investigadores del estudio DIABET-IC

Introduction

All-cause mortality and cardiovascular mortality (CVM) risk can be very high in adults with type 2 diabetes mellitus (DM2) with previous cardiovascular disease (CVD). Our objective was to determine this risk among the different clinical spectrum of CVD.

Material and methods

The DIABET-IC trial is a multicenter, prospective, observational, and analytical study. Consecutive subjects with DM2 attending our outpatients’ clinics were recruited. Data on clinical features, lab test results, and echocardiographic measures were collected.

Patients were categorized depending on the presence and type of CVD: heart failure (HF), coronary artery disease (CAD), cerebrovascular disease (CVD) and peripheral artery disease (PAD).

All-cause mortality and CVM were the dependent variables analyzed. Mortality rate was expressed as deaths per 1000 patients-year. Cox proportional hazards regressions models were used to establish the mortality risk associated with every type of CVD.

Results

We studied a total of 1246 patients (mean age, 6.3 (SD: 9.9) years; 31.6%, female) with an initial prevalence of CVD of 59.3%. A total of 122 deaths (46 due to CVD) occurred at the 2.6-year follow-up. All-cause and CVM rates associated with the presence of PAD (85.6/1000 and 33.6/1000, respectively) and HF (72.9/1000 and 28.7/1000 respectively) were the most elevated of all.

In multivariate analysis, HF increased all-cause mortality risk (HR: 1.63; 95% CI: 1.03-2.58; P = .037) and the risk of CVM (HR: 3.41; 95% CI: 1.68-6.93; P = .001).

Conclusions

Mortality among DM2 patients is highly increased in the presence of HF and PAD. This justifies the screening of these conditions to intensify therapeutic strategies.

导言:既往患有心血管疾病(CVD)的成人 2 型糖尿病(DM2)患者的全因死亡率和心血管死亡率(CVM)风险很高。材料和方法 DIABET-IC 试验是一项多中心、前瞻性、观察性和分析性研究。我们招募了在门诊就诊的 DM2 患者。根据心血管疾病的存在和类型对患者进行分类:心力衰竭(HF)、冠状动脉疾病(CAD)、脑血管疾病(CVD)和外周动脉疾病(PAD)。死亡率以每千名患者年死亡数表示。结果我们共研究了 1246 名患者(平均年龄为 6.3 岁(标清:9.9 岁);31.6% 为女性),其最初的心血管疾病患病率为 59.3%。在 2.6 年的随访中,共有 122 人死亡(46 人死于心血管疾病)。在多变量分析中,高血压增加了全因死亡风险(HR:1.63; 95% CI: 1.03-2.58; P = .037)和 CVM 风险(HR: 3.41; 95% CI: 1.68-6.93; P = .001)。结论 DM2 患者在出现高血压和动脉粥样硬化时死亡率会大幅增加,因此有必要对这些疾病进行筛查,以加强治疗策略。
{"title":"Influencia de la presencia y tipo de enfermedad cardiovascular sobre el riesgo de mortalidad de los pacientes con diabetes tipo 2: estudio DIABET-IC","authors":"José Antonio Gimeno Orna ,&nbsp;Ana Belén Mañas Martínez ,&nbsp;Luis Rodríguez Padial ,&nbsp;Manuel Anguita Sánchez ,&nbsp;Vivencio Barrios ,&nbsp;Javier Muñiz García ,&nbsp;Antonio Pérez Pérez ,&nbsp;en representación de los investigadores del estudio DIABET-IC","doi":"10.1016/j.endinu.2024.03.008","DOIUrl":"10.1016/j.endinu.2024.03.008","url":null,"abstract":"<div><h3>Introduction</h3><p>All-cause mortality and cardiovascular mortality (CVM) risk can be very high in adults with type<!--> <!-->2 diabetes mellitus (DM2) with previous cardiovascular disease (CVD). Our objective was to determine this risk among the different clinical spectrum of CVD.</p></div><div><h3>Material and methods</h3><p>The DIABET-IC trial is a multicenter, prospective, observational, and analytical study. Consecutive subjects with DM2 attending our outpatients’ clinics were recruited. Data on clinical features, lab test results, and echocardiographic measures were collected.</p><p>Patients were categorized depending on the presence and type of CVD: heart failure (HF), coronary artery disease (CAD), cerebrovascular disease (CVD) and peripheral artery disease (PAD).</p><p>All-cause mortality and CVM were the dependent variables analyzed. Mortality rate was expressed as deaths per 1000 patients-year. Cox proportional hazards regressions models were used to establish the mortality risk associated with every type of CVD.</p></div><div><h3>Results</h3><p>We studied a total of 1246 patients (mean age, 6.3 (SD: 9.9) years; 31.6%, female) with an initial prevalence of CVD of 59.3%. A total of 122 deaths (46 due to CVD) occurred at the 2.6-year follow-up. All-cause and CVM rates associated with the presence of PAD (85.6/1000 and 33.6/1000, respectively) and HF (72.9/1000 and 28.7/1000 respectively) were the most elevated of all.</p><p>In multivariate analysis, HF increased all-cause mortality risk (HR: 1.63; 95%<!--> <!-->CI: 1.03-2.58; <em>P</em> <!-->=<!--> <!-->.037) and the risk of CVM (HR: 3.41; 95%<!--> <!-->CI: 1.68-6.93; <em>P</em> <!-->=<!--> <!-->.001).</p></div><div><h3>Conclusions</h3><p>Mortality among DM2 patients is highly increased in the presence of HF and PAD. This justifies the screening of these conditions to intensify therapeutic strategies.</p></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"71 7","pages":"Pages 278-289"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141950214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Revolutionizing the management of diabetes: The promise of connected insulin pens and caps 糖尿病管理的革命性变革:联网胰岛素笔和胰岛素帽的前景
4区 医学 Q3 Nursing Pub Date : 2024-08-01 DOI: 10.1016/j.endinu.2024.04.003
Fernando Gómez-Peralta, Cristina Abreu
{"title":"Revolutionizing the management of diabetes: The promise of connected insulin pens and caps","authors":"Fernando Gómez-Peralta,&nbsp;Cristina Abreu","doi":"10.1016/j.endinu.2024.04.003","DOIUrl":"10.1016/j.endinu.2024.04.003","url":null,"abstract":"","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"71 7","pages":"Pages 275-277"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141954694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of oral supplementation with whey protein on muscle mass in adults with type 2 diabetes mellitus: a systematic review of randomized controlled trials 口服乳清蛋白补充剂对成人 2 型糖尿病患者肌肉质量的影响:随机对照试验的系统回顾
4区 医学 Q3 Nursing Pub Date : 2024-08-01 DOI: 10.1016/j.endinu.2024.04.004
David López-Daza , Natalia López-Ucrós , Cristina Posada-Álvarez , Patricia Savino-Lloreda

Objective

To investigate the overall effect of whey protein supplementation on skeletal muscle mass in adults with type 2 diabetes mellitus (T2DM).

Methods

Systematic review of reports on corporal muscle mass from clinical trials that assessed the use of whey protein supplementation by means of validated techniques in patients with T2DM. PubMed, SCOPUS, Web of Science, LILACS, and SciELO databases were searched up to April 2022. Risk of bias was assessed by the Cochrane Collaboration Risk of Bias tool. We conducted a qualitative synthesis of information.

Results

Four studies (424 participants) that met the selection criteria were identified out of 1,787 records. Of these, 3 studies assessed the total muscle mass using dual-energy X-ray absorptiometry (DXA), and 1 reported changes to the transverse diameter of the vastus lateralis muscle with ultrasound imaging. In the intervention groups, DXA assessments demonstrated an increase in total muscle mass in 3 studies and in the appendicular muscle mass in 2. Changes to the proportion of muscle mass were not seen in the DXA studies and only a discrete difference was seen in the comparative groups studied by ultrasound imaging.

Conclusion

Following the administration of whey protein supplementation in patients with T2DM, a partially positive effect was seen in skeletal muscle mass gain with a moderate certainty of evidence.

方法系统回顾通过有效技术评估 2 型糖尿病(T2DM)患者补充乳清蛋白的临床试验中有关体肌质量的报告。检索了截至 2022 年 4 月的 PubMed、SCOPUS、Web of Science、LILACS 和 SciELO 数据库。偏倚风险由 Cochrane 协作偏倚风险工具进行评估。我们对信息进行了定性综述。结果在 1,787 条记录中确定了四项符合选择标准的研究(424 名参与者)。其中,3 项研究使用双能 X 射线吸收测定法(DXA)评估了总肌肉质量,1 项研究通过超声波成像报告了阔筋膜肌横向直径的变化。在干预组中,3 项研究的 DXA 评估结果显示总肌肉质量增加,2 项研究的阑尾肌肉质量增加。在 DXA 研究中未发现肌肉质量比例的变化,在通过超声波成像研究的比较组中仅发现不连续的差异。
{"title":"Effect of oral supplementation with whey protein on muscle mass in adults with type 2 diabetes mellitus: a systematic review of randomized controlled trials","authors":"David López-Daza ,&nbsp;Natalia López-Ucrós ,&nbsp;Cristina Posada-Álvarez ,&nbsp;Patricia Savino-Lloreda","doi":"10.1016/j.endinu.2024.04.004","DOIUrl":"10.1016/j.endinu.2024.04.004","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the overall effect of whey protein supplementation on skeletal muscle mass in adults with type 2 diabetes mellitus (T2DM).</p></div><div><h3>Methods</h3><p>Systematic review of reports on corporal muscle mass from clinical trials that assessed the use of whey protein supplementation by means of validated techniques in patients with T2DM. PubMed, SCOPUS, Web of Science, LILACS, and SciELO databases were searched up to April 2022. Risk of bias was assessed by the Cochrane Collaboration Risk of Bias tool. We conducted a qualitative synthesis of information.</p></div><div><h3>Results</h3><p>Four studies (424 participants) that met the selection criteria were identified out of 1,787 records. Of these, 3 studies assessed the total muscle mass using dual-energy X-ray absorptiometry (DXA), and 1 reported changes to the transverse diameter of the vastus lateralis muscle with ultrasound imaging. In the intervention groups, DXA<span> assessments demonstrated an increase in total muscle mass in 3 studies and in the appendicular muscle mass in 2. Changes to the proportion of muscle mass were not seen in the DXA studies and only a discrete difference was seen in the comparative groups studied by ultrasound imaging.</span></p></div><div><h3>Conclusion</h3><p>Following the administration of whey protein supplementation in patients with T2DM, a partially positive effect was seen in skeletal muscle mass gain with a moderate certainty of evidence.</p></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"71 7","pages":"Pages 308-316"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141960923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estructura funcional de una unidad de alta resolución de nódulo tiroideo. Impacto económico y resultados de su implantación en un servicio de Endocrinología 高分辨率甲状腺结节单元的功能结构。在内分泌科实施该方案的经济影响和结果。
4区 医学 Q3 Nursing Pub Date : 2024-08-01 DOI: 10.1016/j.endinu.2024.04.002

Background and objective

The high incidence of nodular thyroid pathology has led to growing concern about the economic impact that this pathology represents on the healthcare system. There are conclusive data about the cost-effectiveness of high-resolution units for nodular thyroid pathology; however, their implementation is not homogeneous in the Endocrinology and Nutrition departments of our country. The objective of the present study was to evaluate the economic impact of the implementation of the high-resolution thyroid nodule unit (HRTNU) in our center.

Patients and methods

The present work is a prospective, observational and descriptive study carried out in 1314 patients (82% women, mean age 58 years [DS: 11]) evaluated at the HRTNU during the period of August 2022-August 2023. Demographic data (age and sex) were analyzed, referral center and consultation type, number of total consultations and neck ultrasound performed, number of fine needle aspiration (FNAB) performed, and cytology results were analyzed.

Results

In the period from August 2022 to August 2023, a total of 1314 patients were evaluated (neck ultrasound and clinical consultation) and a total of 133 FNAB were performed, of which only 2.26% were non-diagnostic. Compared to the percentage of unsatisfactory FNAB from the previous year August 2021-July 2022 of 25%, a mean saving of 9,931.43 euros was estimated. 84.47% of the patients evaluated for the first time by the HRTNU were discharged, estimating a mean saving of 133,200 euros.

Conclusions

The implementation of a HRTNU at the Endocrinology and Nutrition departments, coordinated with primary and specialized care, is a cost-effectiveness alternative, as it reduces the number of medical consultations and is accompanied by a higher rate of diagnostic FNAB.

背景和目的甲状腺结节性病变的高发病率使人们越来越关注这种病变对医疗系统造成的经济影响。关于甲状腺结节病理学高分辨率设备的成本效益,已有确凿的数据;然而,在我国的内分泌科和营养科,这些设备的实施情况并不一致。本研究的目的是评估在本中心实施甲状腺结节高分辨单位(HRTNU)的经济影响。患者和方法本研究是一项前瞻性、观察性和描述性研究,在2022年8月至2023年8月期间,在甲状腺结节高分辨单位对1314名患者(82%为女性,平均年龄58岁[DS:11])进行了评估。结果 在2022年8月至2023年8月期间,共有1314名患者接受了评估(颈部超声检查和临床会诊),共进行了133次FNAB检查,其中只有2.26%的检查结果无法确诊。与前一年(2021 年 8 月至 2022 年 7 月)不合格 FNAB 的 25% 相比,估计平均节省了 9931.43 欧元。84.47% 的首次接受 HRTNU 评估的患者已经出院,估计平均可节省 13.32 万欧元。结论在内分泌科和营养科设立 HRTNU,并与初级和专科护理协调,是一种具有成本效益的替代方案,因为它减少了就诊次数,同时提高了 FNAB 的诊断率。
{"title":"Estructura funcional de una unidad de alta resolución de nódulo tiroideo. Impacto económico y resultados de su implantación en un servicio de Endocrinología","authors":"","doi":"10.1016/j.endinu.2024.04.002","DOIUrl":"10.1016/j.endinu.2024.04.002","url":null,"abstract":"<div><h3>Background and objective</h3><p>The high incidence of nodular thyroid pathology has led to growing concern about the economic impact that this pathology represents on the healthcare system. There are conclusive data about the cost-effectiveness of high-resolution units for nodular thyroid pathology; however, their implementation is not homogeneous in the Endocrinology and Nutrition departments of our country. The objective of the present study was to evaluate the economic impact of the implementation of the high-resolution thyroid nodule unit (HRTNU) in our center.</p></div><div><h3>Patients and methods</h3><p>The present work is a prospective, observational and descriptive study carried out in 1314 patients (82% women, mean age 58 years [DS: 11]) evaluated at the HRTNU during the period of August 2022-August 2023. Demographic data (age and sex) were analyzed, referral center and consultation type, number of total consultations and neck ultrasound performed, number of fine needle aspiration (FNAB) performed, and cytology results were analyzed.</p></div><div><h3>Results</h3><p>In the period from August 2022 to August 2023, a total of 1314 patients were evaluated (neck ultrasound and clinical consultation) and a total of 133 FNAB were performed, of which only 2.26% were non-diagnostic. Compared to the percentage of unsatisfactory FNAB from the previous year August 2021-July 2022 of 25%, a mean saving of 9,931.43<!--> <!-->euros was estimated. 84.47% of the patients evaluated for the first time by the HRTNU were discharged, estimating a mean saving of 133,200<!--> <!-->euros.</p></div><div><h3>Conclusions</h3><p>The implementation of a HRTNU at the Endocrinology and Nutrition departments, coordinated with primary and specialized care, is a cost-effectiveness alternative, as it reduces the number of medical consultations and is accompanied by a higher rate of diagnostic FNAB.</p></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"71 7","pages":"Pages 290-297"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141143419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Paraganglioma gangliocítico: a propósito de un caso 神经节细胞性副神经节瘤:病例报告
4区 医学 Q3 Nursing Pub Date : 2024-08-01 DOI: 10.1016/j.endinu.2024.03.006

Paragangliomas (PGLs) are rare and encapsulated neuroendocrine tumors (NET), located in the adrenal gland or the extra-adrenal paraganglia. Extra-adrenal PGLs may develop a gangliocytic component with ganglion cells which are called gangliocytic paragangliomas (GPs). The most common location is the duodenum, and they appear with digestive symptoms or as an incidental finding.

We described a 43 years old patient, with epigastric pain, nausea and vomiting. The CT-scan reveals a nodular image in the duodenum. An ultrasound-guided FNA was performed and the pathological report revealed neuroendocrine cell groups and neural tissue. Surgery was the chosen treatment. As the patient did not present lymphatic or pancreatic parenchyma invasion, radiotherapy (RT) was not administered.

The management of GPs is not well established and multidisciplinary team approach is recommended to lead to therapeutic options. Surgical resection is still key in the treatment, and adjuvant RT may be considered in cases of lymph node invasion.

副神经节瘤(PGLs)是一种罕见的包裹性神经内分泌肿瘤(NET),位于肾上腺或肾上腺外副神经节。肾上腺外副神经节瘤可能含有神经节细胞,被称为神经节细胞副神经节瘤(GPs)。最常见的部位是十二指肠,它们伴随消化道症状出现,或作为偶然发现。CT 扫描显示十二指肠有结节。在超声引导下进行了 FNA 检查,病理报告显示有神经内分泌细胞群和神经组织。选择了手术治疗。由于患者没有淋巴或胰腺实质受侵,因此没有进行放射治疗(RT)。手术切除仍是治疗的关键,淋巴结受侵犯时可考虑辅助 RT。
{"title":"Paraganglioma gangliocítico: a propósito de un caso","authors":"","doi":"10.1016/j.endinu.2024.03.006","DOIUrl":"10.1016/j.endinu.2024.03.006","url":null,"abstract":"<div><p>Paragangliomas (PGLs) are rare and encapsulated neuroendocrine tumors (NET), located in the adrenal gland or the extra-adrenal paraganglia. Extra-adrenal PGLs may develop a gangliocytic component with ganglion cells which are called gangliocytic paragangliomas (GPs). The most common location is the duodenum, and they appear with digestive symptoms or as an incidental finding.</p><p>We described a 43 years old patient, with epigastric pain, nausea and vomiting. The CT-scan reveals a nodular image in the duodenum. An ultrasound-guided FNA was performed and the pathological report revealed neuroendocrine cell groups and neural tissue. Surgery was the chosen treatment. As the patient did not present lymphatic or pancreatic parenchyma invasion, radiotherapy (RT) was not administered.</p><p>The management of GPs is not well established and multidisciplinary team approach is recommended to lead to therapeutic options. Surgical resection is still key in the treatment, and adjuvant RT may be considered in cases of lymph node invasion.</p></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"71 7","pages":"Pages 317-320"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141046585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictive value of circulating miR-409-3p for major adverse cardiovascular events in patients with type 2 diabetes mellitus and coronary heart disease 循环 miR-409-3p 对 2 型糖尿病和冠心病患者主要不良心血管事件的预测价值
4区 医学 Q3 Nursing Pub Date : 2024-07-30 DOI: 10.1016/j.endinu.2024.05.009
Liang Cao , Xiangrong Pan , Ying Li , Wei Jia , Jiayang Huang , Jian Liu

Objectives

To investigate the serum levels of miR-409-3p in patients with type 2 diabetes mellitus (T2DM) complicated with coronary heart disease (CHD) and its effect on high glucose (HG)-induced myocardial cell injury.

Methods

A total of 250 patients with T2DM admitted to our hospital from April 2020 through April 2022 were enrolled as the study subjects, and then grouped into T2DM + CHD (group #1) and T2DM (group #2). Real-time quantitative PCR (RT-qPCR) was used to measure the levels of serum miR-409-3p. The clinical performance of miR-409-3p was evaluated. The human cardiomyocyte AC16 cells were cultured in vitro and treated with HG. MTT assay and flow cytometry were performed to detect cell viability and apoptosis, respectively. Bioinformatic analyses were performed to explore the potential mechanism of miR-409-3p in T2DM complicated with CHD.

Results

The expression level of miR-409-3p was increased in the T2DM + CHD group and had a relative high diagnostic value for distinguishing patients with T2DM + CHD from patients with T2DM alone. Correlation analysis showed that serum miR-409-3p was positively associated with the Gensini score and adverse cardiovascular events; miR-409-3p knockdown alleviated HG-induced AC16 cell damage and reduced cell apoptosis. CREB1, BCL2, and SMAD2 were the top 3 hub genes of miR-409-3p.

Conclusion

Serum miR-409-3p may serve as a potential diagnostic and prognostic biomarker for predicting T2DM complicated with CHD and forecast adverse events. Targeting miR-409-3p may be a novel therapeutic strategy to intervene in the development of T2DM + CHD.
方法选取我院 2020 年 4 月至 2022 年 4 月收治的 250 例 T2DM 患者作为研究对象,将其分为 T2DM + CHD(1 号组)和 T2DM(2 号组)。采用实时定量 PCR(RT-qPCR)技术测定血清 miR-409-3p 的水平。评估了 miR-409-3p 的临床表现。体外培养人心肌细胞 AC16 并用 HG 处理。分别用 MTT 法和流式细胞术检测细胞活力和凋亡。结果 在 T2DM + CHD 组中,miR-409-3p 的表达水平升高,在区分 T2DM + CHD 患者与单纯 T2DM 患者方面具有相对较高的诊断价值。相关分析表明,血清 miR-409-3p 与 Gensini 评分和不良心血管事件呈正相关;敲除 miR-409-3p 可减轻 HG 诱导的 AC16 细胞损伤并减少细胞凋亡。结论血清 miR-409-3p 可作为一种潜在的诊断和预后生物标志物,用于预测 T2DM 并发心脏病和不良事件。以 miR-409-3p 为靶点可能是干预 T2DM + 冠心病发展的一种新型治疗策略。
{"title":"Predictive value of circulating miR-409-3p for major adverse cardiovascular events in patients with type 2 diabetes mellitus and coronary heart disease","authors":"Liang Cao ,&nbsp;Xiangrong Pan ,&nbsp;Ying Li ,&nbsp;Wei Jia ,&nbsp;Jiayang Huang ,&nbsp;Jian Liu","doi":"10.1016/j.endinu.2024.05.009","DOIUrl":"10.1016/j.endinu.2024.05.009","url":null,"abstract":"<div><h3>Objectives</h3><div>To investigate the serum levels of miR-409-3p in patients with type 2 diabetes mellitus (T2DM) complicated with coronary heart disease (CHD) and its effect on high glucose (HG)-induced myocardial cell injury.</div></div><div><h3>Methods</h3><div>A total of 250 patients with T2DM admitted to our hospital from April 2020 through April 2022 were enrolled as the study subjects, and then grouped into T2DM<!--> <!-->+<!--> <!-->CHD (group #1) and T2DM (group #2). Real-time quantitative PCR (RT-qPCR) was used to measure the levels of serum miR-409-3p. The clinical performance of miR-409-3p was evaluated. The human cardiomyocyte AC16 cells were cultured in vitro and treated with HG. MTT assay and flow cytometry were performed to detect cell viability and apoptosis, respectively. Bioinformatic analyses were performed to explore the potential mechanism of miR-409-3p in T2DM complicated with CHD.</div></div><div><h3>Results</h3><div>The expression level of miR-409-3p was increased in the T2DM<!--> <!-->+<!--> <!-->CHD group and had a relative high diagnostic value for distinguishing patients with T2DM<!--> <!-->+<!--> <!-->CHD from patients with T2DM alone. Correlation analysis showed that serum miR-409-3p was positively associated with the Gensini score and adverse cardiovascular events; miR-409-3p knockdown alleviated HG-induced AC16 cell damage and reduced cell apoptosis. CREB1, BCL2, and SMAD2 were the top 3 hub genes of miR-409-3p.</div></div><div><h3>Conclusion</h3><div>Serum miR-409-3p may serve as a potential diagnostic and prognostic biomarker for predicting T2DM complicated with CHD and forecast adverse events. Targeting miR-409-3p may be a novel therapeutic strategy to intervene in the development of T2DM<!--> <!-->+<!--> <!-->CHD.</div></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"71 9","pages":"Pages 372-379"},"PeriodicalIF":0.0,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142535306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incorporación masiva de un sistema automático de administración de insulina en adultos con diabetes tipo 1 previamente tratados con un sistema integrado bomba/sensor por alto riesgo de hipoglucemia 由于低血糖风险较高,在以前使用综合泵/传感器系统治疗的 1 型糖尿病成人患者中大规模引入胰岛素自动给药系统。
4区 医学 Q3 Nursing Pub Date : 2024-07-25 DOI: 10.1016/j.endinu.2024.05.012
Alex Mesa , Daria Roca , Montse Granados , Irene Pueyo , Carla Cabré , Antonio J. Amor , Clara Solà , Olga Matas , Júlia Castanys , Ignacio Conget , Marga Giménez

Introduction

Automatic insulin delivery (AID) systems improve glycemic control and quality of life in individuals with type 1 diabetes (T1D). Our aim was to assess the feasibility, effectiveness, and safety of switching from a sensor-augmented pump (SAP) to AID in T1D subjects at high risk of hypoglycemia.

Materials and methods

A manufacturer-led program consisting of three sessions was implemented. Over three days, all patients completed the first session in-person, in groups of 6-12 people, to receive device training. Subsequently, the automatic mode was activated virtually (session 2), followed by online data download (session 3). Glucometric outcomes were evaluated after one month, along with serious adverse events (SAEs), technical incidents, and perceived satisfaction.

Results

The switch was performed in 125 patients, 56.8% of whom were women, with a mean age of 44.1 ± 14.9 years. 99.2% (n = 124) initialized auto-mode. There was an increase in time in range 70-180 mg/dl (64.3 ± 11.3 vs. 74.7 ± 11.2; P<.001) and a decrease in time below 70 mg/dl (4.1 ± 3.9 vs. 2.0 ± 1.8; p < 0.001) (N = 97). Forty-one related calls were received, with 10 requiring in-person visits. Medtronic technical service handled 92 related calls (0.74 per patient), from 47 different users (37.6%). One event of severe hypoglycemia was recorded as an SAE. Perceived security and satisfaction with the switch process were high in 91% and 92% of patients, respectively.

Conclusions

Massive switch from SAP to AID in T1D patients at high risk of hypoglycemia is feasible and safe through a hybrid program conducted in collaboration with the manufacturer.
导言自动胰岛素输送(AID)系统可改善 1 型糖尿病(T1D)患者的血糖控制和生活质量。我们的目的是评估低血糖高风险 1 型糖尿病患者从传感器增强泵(SAP)转向 AID 的可行性、有效性和安全性。在三天的时间里,所有患者以 6-12 人为一组,亲自参加了第一次培训,接受设备培训。随后,通过虚拟方式启动自动模式(第二阶段),再进行在线数据下载(第三阶段)。一个月后对血糖测量结果、严重不良事件(SAE)、技术事故和满意度进行了评估。99.2%(n = 124)的患者初始化了自动模式。在 70-180 mg/dl 范围内的时间有所增加(64.3 ± 11.3 vs. 74.7 ± 11.2;P< .001),低于 70 mg/dl 的时间有所减少(4.1 ± 3.9 vs. 2.0 ± 1.8;P< 0.001)(N = 97)。共接到 41 个相关电话,其中 10 个需要上门服务。美敦力技术服务部门处理了来自 47 位不同用户(37.6%)的 92 个相关电话(每位患者 0.74 个)。一起严重低血糖事件被记录为 SAE。分别有 91% 和 92% 的患者对转换过程的安全性和满意度较高。结论通过与制造商合作开展混合计划,在低血糖高风险 T1D 患者中将 SAP 大规模转换为 AID 是可行且安全的。
{"title":"Incorporación masiva de un sistema automático de administración de insulina en adultos con diabetes tipo 1 previamente tratados con un sistema integrado bomba/sensor por alto riesgo de hipoglucemia","authors":"Alex Mesa ,&nbsp;Daria Roca ,&nbsp;Montse Granados ,&nbsp;Irene Pueyo ,&nbsp;Carla Cabré ,&nbsp;Antonio J. Amor ,&nbsp;Clara Solà ,&nbsp;Olga Matas ,&nbsp;Júlia Castanys ,&nbsp;Ignacio Conget ,&nbsp;Marga Giménez","doi":"10.1016/j.endinu.2024.05.012","DOIUrl":"10.1016/j.endinu.2024.05.012","url":null,"abstract":"<div><h3>Introduction</h3><div>Automatic insulin delivery (AID) systems improve glycemic control and quality of life in individuals with type 1 diabetes (T1D). Our aim was to assess the feasibility, effectiveness, and safety of switching from a sensor-augmented pump (SAP) to AID in T1D subjects at high risk of hypoglycemia.</div></div><div><h3>Materials and methods</h3><div>A manufacturer-led program consisting of three sessions was implemented. Over three days, all patients completed the first session in-person, in groups of 6-12 people, to receive device training. Subsequently, the automatic mode was activated virtually (session 2), followed by online data download (session 3). Glucometric outcomes were evaluated after one month, along with serious adverse events (SAEs), technical incidents, and perceived satisfaction.</div></div><div><h3>Results</h3><div>The switch was performed in 125 patients, 56.8% of whom were women, with a mean age of 44.1<!--> <!-->±<!--> <!-->14.9 years. 99.2% (n<!--> <!-->=<!--> <!-->124) initialized auto-mode. There was an increase in time in range 70-180<!--> <!-->mg/dl (64.3<!--> <!-->±<!--> <!-->11.3 vs. 74.7<!--> <!-->±<!--> <!-->11.2; <em>P</em>&lt;.001) and a decrease in time below 70<!--> <!-->mg/dl (4.1<!--> <!-->±<!--> <!-->3.9 vs. 2.0<!--> <!-->±<!--> <!-->1.8; p<!--> <!-->&lt;<!--> <!-->0.001) (N<!--> <!-->=<!--> <!-->97). Forty-one related calls were received, with 10 requiring in-person visits. Medtronic technical service handled 92 related calls (0.74 per patient), from 47 different users (37.6%). One event of severe hypoglycemia was recorded as an SAE. Perceived security and satisfaction with the switch process were high in 91% and 92% of patients, respectively.</div></div><div><h3>Conclusions</h3><div>Massive switch from SAP to AID in T1D patients at high risk of hypoglycemia is feasible and safe through a hybrid program conducted in collaboration with the manufacturer.</div></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"71 9","pages":"Pages 390-396"},"PeriodicalIF":0.0,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141845064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Endocrinologia, Diabetes y Nutricion
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1